Combined PET/MR imaging in neurology: MR-based attenuation correction implies a strong spatial bias when ignoring bone

Andersen, 2012, Bone attenuation in brain-PET/MR imaging should be accounted for during attenuation correction and PET reconstruction, Eur. J. Nucl. Med. Mol. Imaging, 39, 174 Beyer, 2011, The future of hybrid imaging-part 3: PET/MR, small-animal imaging and beyond, Insights Imaging, 2, 235, 10.1007/s13244-011-0085-4 Bezrukov, 2013, MR-based PET attenuation correction for PET/MR imaging, Semin. Nucl. Med., 43, 45, 10.1053/j.semnuclmed.2012.08.002 Budinger, 1983, Time-of-flight positron emission tomography: status relative to conventional PET, J. Nucl. Med., 24, 73 Burger, 2002, PET attenuation coefficients from CT images: experimental evaluation of the transformation of CT into PET 511-keV attenuation coefficients, Eur. J. Nucl. Med. Mol. Imaging, 29, 922, 10.1007/s00259-002-0796-3 Carney, 2006, Method for transforming CT images for attenuation correction in PET/CT imaging, Med. Phys., 33, 976, 10.1118/1.2174132 Catana, 2010, Towards implementing an MRI-based PET attenuation–correction method for neurologic studies on the MR–PET brain prototype, J. Nucl. Med., 51, 1431, 10.2967/jnumed.109.069112 Catana, 2012, PET/MRI for neurologic applications, J. Nucl. Med., 53, 1916, 10.2967/jnumed.112.105346 Clark, 2012, Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study, Lancet Neurol., 11, 669, 10.1016/S1474-4422(12)70142-4 Delso, 2011, Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner, J. Nucl. Med., 52, 1914, 10.2967/jnumed.111.092726 Hasselbalch, 1999, No effect of insulin on glucose blood–brain barrier transport and cerebral metabolism in humans, Diabetes, 48, 1915, 10.2337/diabetes.48.10.1915 Heiss, 2009, The potential of PET/MR for brain imaging, Eur. J. Nucl. Med. Mol. Imaging, 36, 105, 10.1007/s00259-008-0962-3 Hitz, 2012, Evaluation of the qualitative performance of PET/MR versus PET/CT in patients with Alzheimer's disease, J. Nucl. Med., 53, 1932 Hitz, 2013, Qualitative performance of an integrated whole-body PET/MR scanner for brain imaging: systematic comparison to conventional PET/CT inpatients examined for suspected dementia with [18F]FDG, J. Nucl. Med. Hofmann, 2009, Towards quantitative PET/MRI: a review of MR-based attenuation correction techniques, Eur. J. Nucl. Med. Mol. Imaging, 39, 93, 10.1007/s00259-008-1007-7 Huang, 1979, Quantitation in positron emission computed tomography: 2. Effects of inaccurate attenuation correction, J. Comput. Assist. Tomogr., 3, 804, 10.1097/00004728-197903060-00018 Jakoby, 2011, Physical and clinical performance of the mCT time-of-flight PET/CT scanner, Phys. Med. Biol., 56, 2375, 10.1088/0031-9155/56/8/004 Kalemis, 2013, Sequential whole-body PET/MR scanner: concept, clinical use, and optimisation after two years in the clinic. The manufacturer's perspective, MAGMA, 26, 5, 10.1007/s10334-012-0330-y Keereman, 2013, Challenges and current methods for attenuation correction in PET/MR, MAGMA, 26, 81, 10.1007/s10334-012-0334-7 Keller, 2013, Image artifacts from MR-based attenuation correction in clinical, whole-body PET/MRI, MAGMA, 26, 173, 10.1007/s10334-012-0345-4 Kinahan, 1998, Attenuation correction for a combined 3D PET/CT scanner, Med. Phys., 25, 2046, 10.1118/1.598392 Krak, 2003, Measuring [(18)F]FDG uptake in breast cancer during chemotherapy: comparison of analytical methods, Eur. J. Nucl. Med. Mol. Imaging, 30, 674, 10.1007/s00259-003-1127-z LaCroix, 1994, Investigation of the use of X-ray CT images for attenuation compensation in SPECT, IEEE Trans. Nucl. Sci., 41, 2793, 10.1109/23.340649 Martinez-Möller, 2009, Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data, J. Nucl. Med., 50, 520, 10.2967/jnumed.108.054726 Ostrowitzki, 2011, Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab, Arch. Neurol., 69, 198, 10.1001/archneurol.2011.1538 Pauleit, 2005, O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas, Brain, 128, 678, 10.1093/brain/awh399 Pichler, 2010, PET/MRI: paving the way for the next generation of clinical multimodality imaging applications, J. Nucl. Med., 51, 333, 10.2967/jnumed.109.061853 Schulz, 2011, Automatic, three-segment, MR-based attenuation correction for whole-body PET/MR data, Eur. J. Nucl. Med. Mol. Imaging, 38, 138, 10.1007/s00259-010-1603-1 Silverman, 2004, Brain 18FFDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging, J. Nucl. Med., 45, 594 Spence, 2004, 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter, J. Nucl. Med., 45, 1653 Wagenknecht, 2013, MRI for attenuation correction in PET: methods and challenges, MAGMA, 26, 99, 10.1007/s10334-012-0353-4 Wahl, 1993, “Anatometabolic” tumor imaging: fusion of FDG PET with CT or MRI to localize foci of increased activity, J. Nucl. Med., 34, 1190 Watson, 1997, A technique for measuring the energy response of a PET tomograph using a compact scattering source, IEEE Trans. Nucl. Sci., 44, 2500, 10.1109/23.656459 Zaidi, 2011, Design and performance evaluation of a whole-body ingenuity TF PET–MRI system, Phys. Med. Biol., 56, 3091, 10.1088/0031-9155/56/10/013